WO2022174323A1 - Clear cannabis-based nanoemulsion - Google Patents
Clear cannabis-based nanoemulsion Download PDFInfo
- Publication number
- WO2022174323A1 WO2022174323A1 PCT/CA2021/050182 CA2021050182W WO2022174323A1 WO 2022174323 A1 WO2022174323 A1 WO 2022174323A1 CA 2021050182 W CA2021050182 W CA 2021050182W WO 2022174323 A1 WO2022174323 A1 WO 2022174323A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- surfactant
- cannabis
- organic phase
- aqueous phase
- nanoemulsion
- Prior art date
Links
- 239000007908 nanoemulsion Substances 0.000 title claims abstract description 102
- 240000004308 marijuana Species 0.000 title 1
- 239000004094 surface-active agent Substances 0.000 claims abstract description 106
- 238000000034 method Methods 0.000 claims abstract description 89
- 238000002360 preparation method Methods 0.000 claims abstract description 70
- 241000218236 Cannabis Species 0.000 claims abstract description 55
- 239000008346 aqueous phase Substances 0.000 claims abstract description 47
- 239000012074 organic phase Substances 0.000 claims abstract description 47
- 239000000203 mixture Substances 0.000 claims abstract description 33
- 239000002904 solvent Substances 0.000 claims abstract description 24
- 238000001704 evaporation Methods 0.000 claims abstract description 14
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims description 33
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims description 33
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims description 33
- 229950011318 cannabidiol Drugs 0.000 claims description 33
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims description 33
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 29
- 229940044476 poloxamer 407 Drugs 0.000 claims description 29
- 229920001992 poloxamer 407 Polymers 0.000 claims description 29
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 29
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 29
- 229940068968 polysorbate 80 Drugs 0.000 claims description 29
- 229920000053 polysorbate 80 Polymers 0.000 claims description 29
- 150000003505 terpenes Chemical class 0.000 claims description 27
- 235000007586 terpenes Nutrition 0.000 claims description 27
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 17
- 239000003755 preservative agent Substances 0.000 claims description 17
- 230000002335 preservative effect Effects 0.000 claims description 15
- 239000011347 resin Substances 0.000 claims description 15
- 229920005989 resin Polymers 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims description 12
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 12
- 229960004242 dronabinol Drugs 0.000 claims description 12
- 239000005711 Benzoic acid Substances 0.000 claims description 11
- 235000010233 benzoic acid Nutrition 0.000 claims description 11
- 229940087168 alpha tocopherol Drugs 0.000 claims description 9
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 229960000984 tocofersolan Drugs 0.000 claims description 9
- 235000004835 α-tocopherol Nutrition 0.000 claims description 9
- 239000002076 α-tocopherol Substances 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- 239000003963 antioxidant agent Substances 0.000 claims description 8
- 235000006708 antioxidants Nutrition 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 235000010199 sorbic acid Nutrition 0.000 claims description 8
- 239000004334 sorbic acid Substances 0.000 claims description 8
- 229940075582 sorbic acid Drugs 0.000 claims description 8
- 230000003078 antioxidant effect Effects 0.000 claims description 7
- 238000002844 melting Methods 0.000 claims description 7
- 230000008018 melting Effects 0.000 claims description 7
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical group CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 6
- 239000010460 hemp oil Substances 0.000 claims description 6
- 230000002572 peristaltic effect Effects 0.000 claims description 6
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims description 4
- IOHPVZBSOKLVMN-UHFFFAOYSA-N 2-(2-phenylethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1CCC1=CC=CC=C1 IOHPVZBSOKLVMN-UHFFFAOYSA-N 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 125000001020 α-tocopherol group Chemical group 0.000 claims 1
- 238000000614 phase inversion technique Methods 0.000 abstract description 4
- 230000008020 evaporation Effects 0.000 description 11
- 229930003827 cannabinoid Natural products 0.000 description 10
- 239000003557 cannabinoid Substances 0.000 description 10
- 235000013361 beverage Nutrition 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- ZROLHBHDLIHEMS-HUUCEWRRSA-N (6ar,10ar)-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCC)=CC(O)=C3[C@@H]21 ZROLHBHDLIHEMS-HUUCEWRRSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- UCONUSSAWGCZMV-HZPDHXFCSA-N Delta(9)-tetrahydrocannabinolic acid Chemical compound C([C@H]1C(C)(C)O2)CC(C)=C[C@H]1C1=C2C=C(CCCCC)C(C(O)=O)=C1O UCONUSSAWGCZMV-HZPDHXFCSA-N 0.000 description 4
- ZROLHBHDLIHEMS-UHFFFAOYSA-N Delta9 tetrahydrocannabivarin Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCC)=CC(O)=C3C21 ZROLHBHDLIHEMS-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 229940065144 cannabinoids Drugs 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical class OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- WIDIPARNVYRVNW-CHWSQXEVSA-N (6ar,10ar)-3,6,6,9-tetramethyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol Chemical compound CC1=CC(O)=C2[C@@H]3C=C(C)CC[C@H]3C(C)(C)OC2=C1 WIDIPARNVYRVNW-CHWSQXEVSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 239000007922 nasal spray Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 229940068965 polysorbates Drugs 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- OJTMRZHYTZMJKX-RTBURBONSA-N (6ar,10ar)-3-heptyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCCCC)=CC(O)=C3[C@@H]21 OJTMRZHYTZMJKX-RTBURBONSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- UVOLYTDXHDXWJU-UHFFFAOYSA-N Cannabichromene Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-UHFFFAOYSA-N 0.000 description 2
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 239000004283 Sodium sorbate Substances 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- WVOLTBSCXRRQFR-DLBZAZTESA-N cannabidiolic acid Chemical compound OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-DLBZAZTESA-N 0.000 description 2
- QXACEHWTBCFNSA-SFQUDFHCSA-N cannabigerol Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-SFQUDFHCSA-N 0.000 description 2
- SVTKBAIRFMXQQF-UHFFFAOYSA-N cannabivarin Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCC)C=C3OC(C)(C)C2=C1 SVTKBAIRFMXQQF-UHFFFAOYSA-N 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000010241 potassium sorbate Nutrition 0.000 description 2
- 239000004302 potassium sorbate Substances 0.000 description 2
- 229940069338 potassium sorbate Drugs 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- LROWVYNUWKVTCU-STWYSWDKSA-M sodium sorbate Chemical compound [Na+].C\C=C\C=C\C([O-])=O LROWVYNUWKVTCU-STWYSWDKSA-M 0.000 description 2
- 235000019250 sodium sorbate Nutrition 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 229940100656 nasal solution Drugs 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Definitions
- the present disclosure relates to cannabis and, more particularly, to cannabis products and preparations such as cannabis-based nanoemulsions and products prepared using such nanoemulsions.
- Cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD), cannabinol (CBN) cannabigerol (CBG), tetrahydrocannabivarin (THCV), tetrahydrocannabinolic acid (THCA), tetrahydrocannabiphorol (THCP), tetrahydrocannabiorcol (THCC), cannabidiolic acid (CBDA), cannabivarin (CBV), cannabichromene (CBC) but not limited to this, cannabinoid extracts and other cannabis constituents, such as terpenes, are sometimes used for the treatment of various medical conditions.
- cannabinoids and terpenes are strongly hydrophobic materials
- water solubibty may present challenges when creating cannabinoid formulations.
- One strategy for solubilizing water-insoluble cannabinoids is oil in water nanoemulsion.
- Cannabinoid emulsification is typically a high-energy process such as high-pressure homogenization, microfluidization or ultrasound energy.
- Such techniques are complicated and require expensive and complicated machinery. Further, such techniques tend to be slow and can cause the active ingredients to become unstable.
- FIG. 1 is a flowchart of an example method of preparing a cannabis-based nanoemulsion in accordance with the present disclosure
- FIG. 2 is a graph illustrating the size distribution of droplets for a THC nanoemulsion
- FIG. 3 is a graph illustrating the size distribution of droplets for a hemp oil nanoemulsion
- FIG. 4 is a graph illustrating the size distribution of droplets for a crystallized CBD nanoemulsion
- FIG. 5 is a graph illustrating the size distribution of droplets for a CBD resin distillate nanoemulsion
- FIG. 6 is a graph illustrating the size distribution of droplets for a CBD resin distillate and crystallized CBD nanoemulsion (1:1 ratio);
- FIG. 7 is a graph illustrating the size distribution of droplets for a CBD resin distillate and crystallized CBD nanoemulsion (1:0.5 ratio);
- FIG. 8 is a flowchart of an example method of preparing a cannabis-based nanoemulsion in accordance with the present disclosure.
- FIG. 9 is a graph illustrating the size distribution of droplets for hemp oil in accordance with the present disclosure.
- a method of preparing a cannabis-based nanoemulsion may include: combining a surfactant preparation with a cannabis-based preparation to create a mixture; combining the mixture with a solvent to create an organic phase; adding the organic phase to an aqueous phase; and evaporating the solvent.
- This method may be referred to as a spontaneous nanoemulsification method.
- the surfactant preparation may include polysorbate 80.
- the surfactant preparation may include poloxamer 407.
- the surfactant preparation may include polysorbate 80 and poloxamer 407 in a ratio of between 3 parts polysorbate 80 to 0.75 part poloxamer 407 (3:0.75) and 4 parts polysorbate 80 to 1 part poloxamer 407 (4:1).
- the surfactant preparation may include a co- surfactant.
- the co-surfactant may be diethylene glycol monoethyl ether.
- the co-surfactant may be combined in the surfactant preparation with one or more surfactants in a ratio of between 4.5 parts surfactant to 0.75 parts co-surfactant and 5 parts surfactant to 1.6 parts co-surfactant.
- the cannabis-based preparation may include one or more of: tetrahydrocannabinol (TF1C) distilled resin; hemp oil; cannabidiol (CBD) distilled resin; [0020] cannabidiol (CBD) distilled crystalline; or terpenes.
- TF1C tetrahydrocannabinol
- CBD cannabidiol
- CBD cannabidiol
- the cannabis-based preparation may include an antioxidant.
- the antioxidant may be alpha tocopherol.
- the cannabis-based preparation may include alpha tocopherol without any other oily carrier.
- the solvent used in the method may be water- miscible.
- the solvent may, for example, be ethanol or acetone.
- the method may include, prior to adding the organic phase to the aqueous phase, filtering the mixture.
- the filtering may be performed using a 0.22 to 0.45 micrometer membrane filter.
- the method may include, prior to adding the organic phase to the aqueous phase, preparing the aqueous phase by combining a preservative with water.
- the preservative may be benzoic acid, a benzoic acid derivative, cetylpyridium chloride or sorbic acid
- the organic phase may be added to the aqueous phase in a dropwise manner.
- the organic phase may be added to the aqueous phase at a rate of not faster than 1.4 mL per minute to make lOOmL batch of concentrated nanoemulsion.
- the mixture organic phase be added to the aqueous phase using a peristaltic pump.
- the cannabis-based nanoemulsion may be prepared without the use of any of a homogenizer, sonicator and microfluidizer. [0029] Also described is a cannabis-based nanoemulsion produced according to the described methods.
- the present application describes a further method of preparing a cannabis-based nanoemulsion.
- the further method may include: preparing a surfactant preparation by melting one or more surfactants; combining the surfactant preparation with a cannabis-based preparation to create an organic phase; and adding an aqueous phase to the organic phase.
- a phase inversion method Such a method may be referred to as a phase inversion method.
- preparing the surfactant preparation may include, after melting, stirring the melted surfactants until the surfactant preparation becomes clear. [0032] In some implementations, preparing the surfactant preparation may include, after the surfactant becomes clear, cooling the surfactant to room temperature prior to adding the aqueous phase to the organic phase.
- the one or more surfactants may include polysorbate 80. Ins some implementations, the one or more surfactants includes poloxamer 407. [0034] In some implementations the one or more surfactants includes polysorbate 80 and poloxamer 407 in a ratio of between 3 parts polysorbate 80 to 0.75 part poloxamer 407 (3:0.75) and four parts polysorbate 80 to one part poloxamer 407 (4:1).
- the cannabis-based preparation may be a terpene-based preparation.
- the method may include, prior to adding the aqueous phase to the organic phase, preparing the aqueous phase by combining a preservative with water.
- the preservative may be benzoic acid, a benzoic acid derivative, cetylpyridium chloride or sorbic acid.
- the aqueous phase may be added to the organic phase in a dropwise manner.
- the aqueous phase may be added to the organic phase at a rate of not faster than 1.4 mL per minute to make 100 mL batch of concentrated nanoemulsion.
- the aqueous phase may be added to the organic phase using a peristaltic pump.
- the cannabis-based nanoemulsion may be prepared without the use of any of a homogenizer, sonicator and microfluidizer.
- nanoemulsions prepared according to the described techniques may be clear nanoemulsions. Further, such nano-emulsions may be prepared without using a homogenizer. The described techniques may allow nanoemulsions to be prepared at a low cost and without the need for specialized equipment, such as a homogonizer.
- Nanoemulsions produced using techniques described herein may, for example, be diluted in a matrix of choice. For example, nanoemulsions may be used in beverages, sublingual strips, nasal sprays, cosmetics, or topical products.
- one milliliter of a 1% stock solution of nanoemulsion may be diluted with a 354 milliliter beverage to produce a 355 milliliter beverage with 10 milligrams of cannabinoid.
- FIG. 1 illustrates a method 100 of preparing a cannabis-based nanoemulsion.
- the method 100 may, in at least some embodiments, be used to create a clear nanoemulsion. That is, the nanoemulsion obtained using the method 100 may be transparent. For example, the nanoemulsion may be clear and may resemble water in appearance.
- the method 100 may, in at least some embodiments, be used to produce a cannabis-based nanoemulsion that has small droplet sizes.
- a small droplet size may enhance the bioavailability of the nanoemulsion.
- the nanoemulsion may have droplets in a diameter range that is less than 100 nanometers.
- a surfactant preparation is combined with a cannabis-based preparation to create a mixture.
- the surfactant preparation may include polysorbate 80.
- the surfactant preparation may include poloxamer 407.
- the surfactant preparation includes polysorbate 80 and poloxamer 407 in a ratio of between 3 parts polysorbate 80 to one part poloxamer 407 (3:1) to four parts polysorbate 80 to one part poloxamer 407 (4:1).
- the surfactant preparation includes polysorbate 80 and poloxamer 407 in a ratio of between three parts polysorbate 80 to 0.75 parts poloxamer 407 and four parts polysorbate 80 to one part poloxamer 407 (4:1).
- the total percent surfactant is preferentially 5% w/v or more in the final non- diluted solution. However, 5% to 10% w/v may, for example, be used to generate a concentrated nanoemulsion containing more than 1% active substance.
- the surfactant preparation includes a co surfactant.
- the co-surfactant may be a diethylene glycol derivative such as ethylene- series of glycol ether; for example, a diethylene glycol monoethyl ether such as Transcutol HP(TM) or Carbitol.
- the co-surfactant may take other forms.
- the co-surfactant may be combined in the surfactant preparation with the one or more surfactants in a ratio of between 4.5 parts surfactant to 0.75 parts co-surfactant and 5 parts surfactant to 1.6 parts co-surfactant.
- a concentrated nanoemulsion produced according to a method described herein may preferentially contain: 0.5% to 1% w/v active substance, 5% surfactant and 94% water. Higher concentrations of surfactant may be used to load more active substance.
- surfactants described above have been found to create a clear nanoemulsion when used according to the techniques described herein.
- Other surfactants may be used to create a nanoemulsion having a small droplet size, but at least some such surfactants may not yield a clear nanoemulsion.
- the surfactant preparation may contain any of polysorbates 20, 40, 60, 80, 85 and/or any of poloxamers 105, 188, 238, 331, 333, 334, 335, 338, 407 and/or any of and polyethylene glycols 200, 300, 400, 600.
- the cannabis-based preparation may be or include tetrahydrocannabinol (THC) resin. Additionally or alternatively, the cannabis-based preparation may be or include hemp oil, cannabidiol (CBD) resin, cannabidiol (CBD) or THC distilled, THC or CBD crystalline, any kinds of rare cannabinoids such as but not limited to cannabinol (CBN), cannabigerol (CBG), tetrahydrocannabivarin (THCV), tetrahydrocannabinolic acid (THCA), tetrahydrocannabiphorol (THCP), Tetrahydrocannabinol (THCC), cannabidiolic acid (CBDA), cannabivarin (CBV), cannabichromene (CBC) and combinations thereof and/or terpenes.
- CBD cannabidiol
- CBD cannabidiol
- THC THC or CBD crystalline
- any kinds of rare cannabinoids
- the cannabis-based preparation may include an antioxidant.
- the antioxidant may be or include alpha tocopherol (which may also be referred to as Vitamin E).
- Other antioxidants may be used instead of or in addition to alpha tocopherol.
- the cannabis-based preparation may include any one or a combination of: ascorbyl palmitate, butylated hydroxytoluene, or butylated hydroxyanisole.
- the cannabis preparation includes alpha tocopherol without any other oily carrier.
- Alpha tocopherol may be added to prevent oxidation.
- the amount of alpha tocopherol may, for example, be approximately 0.04% by volume of the amount of the cannabis-based preparation, but the concentration may be varied.
- an organic phase is prepared. More specifically, the mixture created at step 102 is combined with a solvent.
- the mixture may be dissolved in a water miscible solvent such as ethanol or acetone.
- a water miscible solvent such as ethanol or acetone.
- Ethanol has been used for reasons of volatility and safety but other solvents may be used.
- the mixture may be dissolved in ethanol which is, conveniently, safe to use and easy to evaporate.
- the mixture that includes the solvent is passed through a filter to remove insoluble material.
- the mixture may be passed through a 0.22 to 0.45 micrometer membrane filter. Any material separated out by the filter may be discarded.
- an aqueous phase is prepared.
- the aqueous phase is prepared by measuring an appropriate volume of water by calculating the volume of all ingredients based on the formulation and then calculating an amount of water required for the formulation.
- a chelating agent and a preservative may be included in the aqueous phase.
- Ethylenediaminetetraacetic acid (EDTA) is a chelating agent that can chelate a small amount of metal to prevent oxidation and increase the effects of the antioxidant.
- the preservative may, for example, be benzoic acid or sorbic acid. Other preservatives may be used.
- the preservative may be any one or a combination of: 1) Sorbic acid and its salts like sodium sorbate, potassium sorbate; 2) Benzoic acid and Benzoic acid derivatives like sodium benzoate; 3) Parabens: Methyl paraben, Propyl paraben; 4) Benzalkonium chloride; and 5) Cetylpryidinium bromide [0058] EDTA may have a concentration of approximately 0.005% to 0.01% and the benzoic acid may have a concentration of approximately 0.02% to 0.5% and the sorbic acid may have a concentration of 0.1 -0.2%.
- the organic phase i.e. the mixture that includes the solvent
- the organic phase is slowly added to the aqueous phase (e.g., in a dropwise manner).
- the organic phase is added to the aqueous phase dropwise, preferably at a rate of no faster than 1.4 milliliters per minute (organic phase) to make 100 milliliter batch of concentrated nanoemulsion. If the organic phase is added to the aqueous phase too rapidly, there may not be enough time for the solvent to diffuse into the water which may result in a final product having a larger droplet size and/or that may not be clear.
- the organic phase may be added to the aqueous phase using a peristaltic pump, a syringe or mist.
- the organic phase may be added to the aqueous phase under stirring.
- the stirring may, for example, be performed with any kind of mechanical agitator.
- stirring may continue to ensure diffusion of the organic phase is complete. For example, stirring may continue for thirty minutes or more.
- evaporation is performed on the mixture that includes the organic phase and the aqueous phase.
- the water miscible solvent such as ethanol or acetone
- the evaporation may continue for 30 minutes or more.
- the evaporation step may end when all of the solvent is evaporated. While the evaporation step could continue even after the solvent is completely removed, continuing the evaporation after the solvent is removed may have an adverse effect on stability of the nanoemulsion and/or may unnecessarily use energy or equipment.
- the volume of the mixture remaining after evaporation may be measured and water may be added to adjust the volume. For example, for a 100 mL batch of nanoemulsion, if 1 to 2 mL were lost on evaporation (at step 112), as may be determined using a graduated cylinder, the volume may be adjusted 1 to 2 mL with water to account for the loss of volume due to evaporation.
- the nanoemulsion may be added to and stored in one or more closed containers.
- the container may be configured to block external light and/or may prevent oxygen from entering the container.
- the container may be an amber tinted or colored container.
- the container may be nitrogen flushed or vacuum sealed to remove any gaseous oxygen from within the container.
- FIG. 2 a graph illustrating the size distribution of droplets for a TF1C nanoemulsion containing 7.5 mg of TF1C per milliliter is illustrated.
- the nanoemulsion could have other amounts of TF1C.
- the nanoemulsion may preferably contain 5 mg to 7.5 mg of TF1C per m though other amounts of TF1C are also possible.
- a stable nanoemulsion may be made up to at least 10 mg/mL if the starting material is pure isolate.
- the nanoemulsion has been prepared using the techniques described herein and it may be seen that the droplet size is relatively small (e.g., less than 100 nanometers).
- FIG. 3 2 for TF1C are also illustrated for hemp oil (FIG. 3) containing 1% weight by volume Flemp Oil, and for CBD crystallized nanoemulsion (FIG. 4) containing 7.5 mg of crystallized CBD per milliliter, and for CBD resin nanoemulsion (FIG. 5) containing 10 mg CBD resin per milliliter, and for CBD resin and CBD crystallized nanoemulsion (FIG. 6) containing 5 mg of CBD resin and CBD crystallized per milliliter and CBD crystallized nanoemulsion (FIG. 7) containing 7.5 mg of CBD resin and CBD crystallized per milliliter.
- FIG. 8 illustrates a further method 800 of preparing a cannabis-based nanoemulsion.
- the method 800 may, for example, be used to prepare a terpene-based nanoemulsion.
- the method 800 of FIG. 8 does not use a solvent and does not require an evaporation step.
- the method 800 of FIG. 8 may avoid evaporation of certain ingredients, such as terpenes.
- a surfactant preparation may be prepared by melting one or more surfactants.
- one or more surfactants may be melted at approximately forty five (45) degrees Celsius.
- the one or more surfactants may be melted at above forty three (43) degrees Celsius.
- the one or more surfactants may be melted at between 43 and 46 degrees Celsius.
- the surfactants used in the surfactant preparation may preferably include polysorbate 80 and poloxamer 407.
- the surfactant preparation preferentially contains polysorbate 80, and may also include (but not limited to) various forms of: polysorbates (20, 40, 60, 85), any kinds of poloxamers (105, 188, 238, 331, 333, 334, 335, 338, 407) and polyethylene glycols (200, 300, 400, 600).
- the surfactant preparation may include poloxamer 407.
- the surfactant preparation includes polysorbate 80 and poloxamer 407 in a ratio of between three 3 parts polysorbate 80 to 0.75 part poloxamer 407 (3:0.75) to four (4) parts polysorbate 80 to one (1) part poloxamer 407 (4:1).
- the surfactant preparation includes a co surfactant.
- the co- surfactant may be a diethylene glycol derivative such as an ethylene- series of glycol ether.
- it may be or include diethylene glycol monoethyl ether such as Transcutol FIP(TM) or Carbitol.
- Other co- surfactants may be used.
- the co surfactant may be combined in the surfactant preparation with the one or more surfactants in a ratio of between 4.5 parts surfactant to 0.5 parts co-surfactant and 5 parts surfactant to 1.6 parts co-surfactant.
- the surfactants may be stirred (during step 802) until the mixture (which may also be referred to as the surfactant preparation) becomes clear. It has been found that clarity occurs after approximately five minutes of stirring in laboratory environments. Flowever, the length of time required may vary. Most typically, the length of time is less than 15 minutes at 45 degrees Celsius depending on the level of impurities in the cannabis extract, with resins containing waxes taking longer.
- the mixture may be cooled.
- the mixture may be cooled to room temperature (about 20 to 25 degrees Celsius) during step 802. Cooling of the mixture may prevent loss of the terpenes.
- the surfactant preparation that is prepared at step 802 may be combined with a cannabis-based preparation at step 804 to create a mixture, which may be referred to as the organic phase.
- the cannabis-based preparation may be a terpene-based preparation such as a terpene concentrate.
- Terpenes are organic compounds that impart aroma and flavor to cannabis plants.
- the term terpene concentrate pertains to the concentrated terpenes rendered from different cannabis strains.
- the described method should be compatible with terpene concentrates from any cannabis strain, terpene isolates (single terpenes isolated from a concentrated mixture), and formulated terpene mixtures derived from the combination of a set of desired terpene isolates.
- the phase inversion method has been used to make different kinds of cannabinoid nanoemulsions including those containing terpenes.
- nanoemulsions with 1-2% terpene concentrates are made with different types of terpenes using the method 800, and diluted into different water based mixtures such as beverages. This method may be particularly useful for preparation of terpene nanoemulsions because of the volatile nature of terpenes, which makes the use of evaporation and heat inappropriate.
- an aqueous phase is prepared.
- the aqueous phase is prepared by measuring an appropriate volume of water (e.g., by calculating the volume of all ingredients based on the formulation and then calculating how much water is needed for the formulation and adding EDTA and a preservative in at least some embodiments.
- the preservative may, for example, be benzoic acid, such as benzoic acid at a concentration of 0.05%.
- the preservative may, for example, aid in avoiding microbial growth and prevent oxidation. Other preservatives may be used.
- the preservative may be any one or a combination of: 1) Sorbic acid and its salts like sodium sorbate, potassium sorbate; 2) Benzoic acid and Benzoic acid derivatives like sodium benzoate; 3) Parabens: Methyl paraben, Propyl paraben; 4) Benzalkonium chloride (for non-oral applications); and 5) Cetylpryidinium bromide
- the aqueous phase is slowly added to the organic phase (i.e., the mixture that includes the surfactant preparation and the cannabis-based preparation).
- the aqueous phase may be added in a dropwise manner.
- the aqueous phase may preferably be added no faster than 1.4 mL per minute to make 100 mL batch of concentrated nanoemulsion. If the aqueous phase is added to the organic phase too rapidly, there may not be enough time for the organic phase to diffuse in the water which may result in a final product having a large droplet size and/or that may not be clear.
- the aqueous phase may be added to the organic phase using a peristaltic pump or with a syringe.
- stirring may occur to ensure that diffusion of the organic phase is complete. For example, stirring may continue for thirty minutes or more.
- the nanoemulsion may be added to and stored in one or more closed containers.
- the container may be configured to block external light and/or may prevent oxygen from entering the container.
- the container may be an amber tinted or coloured container.
- the container may be nitrogen flushed or vacuum sealed to remove any gaseous oxygen from within the container.
- the nanoemulsions prepared according to the methods 100, 800 described herein may be prepared without the use of a homogenizer or other sophisticated equipment (e.g., without the use of a homogenizer, sonicator or microfluidizer).
- the nanoemulsions may be clear and/or may have a small droplet size. A small droplet size may allow for a faster onset for active ingredients in the nanoemulsions. That is, the effects of the CBD, THC and/or terpenes may occur more rapidly where the droplet size is relatively small.
- the nanoemulsions prepared using the techniques described herein may be in liquid form. However, such nanoemulsions may be processed into another form, such as a solid form. For example, the liquids may be processed to create a sublingual film or spray, lotions, ointments and cosmetics, or a foam.
- the nanoemulsions prepared according to the methods described herein may be stable in water or soda. This may, for example, allow the nanoemulsion to be added to water or a soda before being ingested or otherwise consumed.
- the nanoemulsions prepared according to the methods described herein may be sterilized using filtration (i.e., by passing the nanoemulsions through a filter such as a 0.45 micrometer filter). Filtration is possible due to the small droplet size associated with nanoemulsions. Sterilization by filtration may be used instead of, for example, thermal sterilization techniques.
- methods described herein may include sterilizing a nanoemulsion prepared according to the techniques described herein using filtration.
- the cannabis-based concentrated stock nanoemulsions described herein can be diluted in a matrix of choice like beverages, sublingual strips, nasal sprays, cosmetic or topical products.
- a matrix of choice like beverages, sublingual strips, nasal sprays, cosmetic or topical products.
- 1 ml of 1% stock solution could be diluted with 354 ml beverage for a 355 ml can with 10 mg cannabinoid.
- the nanoemulsions described herein may be used by a human or animal.
- the nanoemulsions may be used as oral, buccal, topical, rectal, nasal solution and/or spray, eyedrops, etc.
- the nanoemulsion may be administered, for example, for medicinal benefits.
- the nanoemulsions may, for example, be added to a food product such as a baked good or a beverage, such as water, soda, non-alcoholic beer, breezers, or coolers.
- methods of creating products such as beverages, edibles, cosmetics, topicals, sublingual sprays, nasal sprays, eye drops, etc. using concentrated nanoemulsions prepared using techniques described herein are contemplated.
- preparing such products may include diluting the concentrated nanoemulsions.
- the nanoemulsions described herein may be used, for example, to treat a variety of medical conditions.
- the nanoemulsions may be used to treat one or more of: multiple sclerosis (MS), nausea, vomiting, loss of appetite for F1IV patients and/or seizures.
- MS multiple sclerosis
- nausea, vomiting, loss of appetite for F1IV patients and/or seizures may be used to treat other conditions apart from those specifically recited herein.
- the nanoemulsions described herein may be used by a human or animal.
- the nanoemulsions may be ingested (i.e., used orally).
- the nanoemulsions may be administered, for example, for medicinal benefits.
- the nanoemulsions described herein may be used, for example, to treat a variety of medical conditions.
- the nanoemulsions described herein may be used for the treatment or amelioration of symptoms of medical conditions.
- symptoms may include any one or a combination of inflammation, lack of appetite, nausea, vomiting, pain including chronic pain, or muscle spasms.
- the cannabis based products described herein may be used as part of a treatment plan (including to manage symptoms) for conditions such as multiple sclerosis, glaucoma, acquired immunodeficiency syndrome (AIDS), neuropathic conditions, cancer, acne, diseases of malnutrition, arthritis, or spinal cord injury. It can be appreciated that cannabis based products can be used for treatment of other symptoms or other conditions.
- the nanoemulsions described herein may be used for the treatment of any one or more medical conditions or systems, such as those listed above.
- the nanoemulsions may be ingested by a patient suffering from such a symptom or condition.
- the various embodiments presented above are merely examples. Variations of the innovations described herein will be apparent to persons of ordinary skill in the art, such variations being within the intended scope of the present application.
- features from one or more of the above-described example embodiments may be selected to create alternative example embodiments including a sub-combination of features which may not be explicitly described above.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Botany (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Cannabis-based clear nanoemulsions and methods of preparing cannabis-based nanoemulsions without a homogenizer are described. In an aspect, a method of preparing a cannabis-based nanoemulsion includes combining a surfactant preparation with a cannabis-based preparation to create a mixture; combining the mixture with a solvent to create an organic phase; adding the organic phase to an aqueous phase; and evaporating the solvent. In another aspect, a phase inversion method of preparing a nanoemulsion is described.
Description
Clear Cannabis-Based Nanoemulsion
TECHNICAL FIELD
[OOOl] The present disclosure relates to cannabis and, more particularly, to cannabis products and preparations such as cannabis-based nanoemulsions and products prepared using such nanoemulsions.
BACKGROUND
[0002] Cannabinoids, such as tetrahydrocannabinol (THC) and cannabidiol (CBD), cannabinol (CBN) cannabigerol (CBG), tetrahydrocannabivarin (THCV), tetrahydrocannabinolic acid (THCA), tetrahydrocannabiphorol (THCP), tetrahydrocannabiorcol (THCC), cannabidiolic acid (CBDA), cannabivarin (CBV), cannabichromene (CBC) but not limited to this, cannabinoid extracts and other cannabis constituents, such as terpenes, are sometimes used for the treatment of various medical conditions. However, since cannabinoids and terpenes are strongly hydrophobic materials, water solubibty may present challenges when creating cannabinoid formulations. [0003] One strategy for solubilizing water-insoluble cannabinoids is oil in water nanoemulsion. Cannabinoid emulsification is typically a high-energy process such as high-pressure homogenization, microfluidization or ultrasound energy. Such techniques are complicated and require expensive and complicated machinery. Further, such techniques tend to be slow and can cause the active ingredients to become unstable. [0004] Thus, there is a need for improved techniques for creating cannabis-based nanoemulsions.
BRIEF DESCRIPTION OF THE DRAWINGS
[0005] Reference will now be made, by way of example, to the accompanying drawings which show embodiments of the present application, and in which:
[0006] FIG. 1 is a flowchart of an example method of preparing a cannabis-based nanoemulsion in accordance with the present disclosure;
[0007] FIG. 2 is a graph illustrating the size distribution of droplets for a THC nanoemulsion; [0008] FIG. 3 is a graph illustrating the size distribution of droplets for a hemp oil nanoemulsion;
[0009] FIG. 4 is a graph illustrating the size distribution of droplets for a crystallized CBD nanoemulsion;
[0010] FIG. 5 is a graph illustrating the size distribution of droplets for a CBD resin distillate nanoemulsion;
[0011] FIG. 6 is a graph illustrating the size distribution of droplets for a CBD resin distillate and crystallized CBD nanoemulsion (1:1 ratio);
[0012] FIG. 7 is a graph illustrating the size distribution of droplets for a CBD resin distillate and crystallized CBD nanoemulsion (1:0.5 ratio); [0013] FIG. 8 is a flowchart of an example method of preparing a cannabis-based nanoemulsion in accordance with the present disclosure; and
[0014] FIG. 9 is a graph illustrating the size distribution of droplets for hemp oil in accordance with the present disclosure.
[0015] Like reference numerals are used in the drawings to denote like elements and features.
DETAILED DESCRIPTION OF EXAMPLE EMBODIMENTS
[0016] In an aspect a method of preparing a cannabis-based nanoemulsion is described. In an aspect, the method may include: combining a surfactant preparation with a cannabis-based preparation to create a mixture; combining the mixture with a solvent to
create an organic phase; adding the organic phase to an aqueous phase; and evaporating the solvent. This method may be referred to as a spontaneous nanoemulsification method. [0017] The surfactant preparation may include polysorbate 80. The surfactant preparation may include poloxamer 407. For example, the surfactant preparation may include polysorbate 80 and poloxamer 407 in a ratio of between 3 parts polysorbate 80 to 0.75 part poloxamer 407 (3:0.75) and 4 parts polysorbate 80 to 1 part poloxamer 407 (4:1). [0018] The surfactant preparation may include a co- surfactant. The co-surfactant may be diethylene glycol monoethyl ether. The co-surfactant may be combined in the surfactant preparation with one or more surfactants in a ratio of between 4.5 parts surfactant to 0.75 parts co-surfactant and 5 parts surfactant to 1.6 parts co-surfactant. [0019] The cannabis-based preparation may include one or more of: tetrahydrocannabinol (TF1C) distilled resin; hemp oil; cannabidiol (CBD) distilled resin; [0020] cannabidiol (CBD) distilled crystalline; or terpenes.
[0021] The cannabis-based preparation may include an antioxidant. The antioxidant may be alpha tocopherol. The cannabis-based preparation may include alpha tocopherol without any other oily carrier.
[0022] In at least some implementations, the solvent used in the method may be water- miscible. The solvent may, for example, be ethanol or acetone.
[0023] In some implementations, the method may include, prior to adding the organic phase to the aqueous phase, filtering the mixture. The filtering may be performed using a 0.22 to 0.45 micrometer membrane filter.
[0024] In some implementations, the method may include, prior to adding the organic phase to the aqueous phase, preparing the aqueous phase by combining a preservative with water. The preservative may be benzoic acid, a benzoic acid derivative, cetylpyridium chloride or sorbic acid
[0025] In some implementations, the organic phase may be added to the aqueous phase in a dropwise manner.
[0026] In some implementations, the organic phase may be added to the aqueous phase at a rate of not faster than 1.4 mL per minute to make lOOmL batch of concentrated nanoemulsion.
[0027] In some implementations, the mixture organic phase be added to the aqueous phase using a peristaltic pump.
[0028] In some implementations, the cannabis-based nanoemulsion may be prepared without the use of any of a homogenizer, sonicator and microfluidizer. [0029] Also described is a cannabis-based nanoemulsion produced according to the described methods.
[0030] In another aspect, the present application describes a further method of preparing a cannabis-based nanoemulsion. The further method may include: preparing a surfactant preparation by melting one or more surfactants; combining the surfactant preparation with a cannabis-based preparation to create an organic phase; and adding an aqueous phase to the organic phase. Such a method may be referred to as a phase inversion method.
[0031] In some implementations, preparing the surfactant preparation may include, after melting, stirring the melted surfactants until the surfactant preparation becomes clear. [0032] In some implementations, preparing the surfactant preparation may include, after the surfactant becomes clear, cooling the surfactant to room temperature prior to adding the aqueous phase to the organic phase.
[0033] In some implementations, the one or more surfactants may include polysorbate 80. Ins some implementations, the one or more surfactants includes poloxamer 407.
[0034] In some implementations the one or more surfactants includes polysorbate 80 and poloxamer 407 in a ratio of between 3 parts polysorbate 80 to 0.75 part poloxamer 407 (3:0.75) and four parts polysorbate 80 to one part poloxamer 407 (4:1).
[0035] The cannabis-based preparation may be a terpene-based preparation.
[0036] In some implementations, the method may include, prior to adding the aqueous phase to the organic phase, preparing the aqueous phase by combining a preservative with water. The preservative may be benzoic acid, a benzoic acid derivative, cetylpyridium chloride or sorbic acid.
[0037] The aqueous phase may be added to the organic phase in a dropwise manner. For example, the aqueous phase may be added to the organic phase at a rate of not faster than 1.4 mL per minute to make 100 mL batch of concentrated nanoemulsion. The aqueous phase may be added to the organic phase using a peristaltic pump.
[0038] The cannabis-based nanoemulsion may be prepared without the use of any of a homogenizer, sonicator and microfluidizer.
[0039] Also described is a cannabis-based nanoemulsion produced according to the described methods.
[0040] Conveniently, nanoemulsions prepared according to the described techniques may be clear nanoemulsions. Further, such nano-emulsions may be prepared without using a homogenizer. The described techniques may allow nanoemulsions to be prepared at a low cost and without the need for specialized equipment, such as a homogonizer. [0041 ] Nanoemulsions produced using techniques described herein may, for example, be diluted in a matrix of choice. For example, nanoemulsions may be used in beverages, sublingual strips, nasal sprays, cosmetics, or topical products. By way of example, one milliliter of a 1% stock solution of nanoemulsion may be diluted with a 354 milliliter beverage to produce a 355 milliliter beverage with 10 milligrams of cannabinoid.
[0042] Reference is first made to FIG. 1, which illustrates a method 100 of preparing a cannabis-based nanoemulsion. The method 100 may, in at least some embodiments, be used to create a clear nanoemulsion. That is, the nanoemulsion obtained using the method 100 may be transparent. For example, the nanoemulsion may be clear and may resemble water in appearance.
[0043] The method 100 may, in at least some embodiments, be used to produce a cannabis-based nanoemulsion that has small droplet sizes. A small droplet size may enhance the bioavailability of the nanoemulsion.
[0044] For example, the nanoemulsion may have droplets in a diameter range that is less than 100 nanometers.
[0045] At step 102, a surfactant preparation is combined with a cannabis-based preparation to create a mixture. The surfactant preparation may include polysorbate 80. The surfactant preparation may include poloxamer 407. In at least some embodiments, the surfactant preparation includes polysorbate 80 and poloxamer 407 in a ratio of between 3 parts polysorbate 80 to one part poloxamer 407 (3:1) to four parts polysorbate 80 to one part poloxamer 407 (4:1). In at least some embodiments, the surfactant preparation includes polysorbate 80 and poloxamer 407 in a ratio of between three parts polysorbate 80 to 0.75 parts poloxamer 407 and four parts polysorbate 80 to one part poloxamer 407 (4:1).
[0046] The total percent surfactant is preferentially 5% w/v or more in the final non- diluted solution. However, 5% to 10% w/v may, for example, be used to generate a concentrated nanoemulsion containing more than 1% active substance.
[0047] In at least some embodiments, the surfactant preparation includes a co surfactant. The co-surfactant may be a diethylene glycol derivative such as ethylene- series of glycol ether; for example, a diethylene glycol monoethyl ether such as Transcutol
HP(TM) or Carbitol. The co-surfactant may take other forms. The co-surfactant may be combined in the surfactant preparation with the one or more surfactants in a ratio of between 4.5 parts surfactant to 0.75 parts co-surfactant and 5 parts surfactant to 1.6 parts co-surfactant.
[0048] In at least some embodiments, a concentrated nanoemulsion produced according to a method described herein may preferentially contain: 0.5% to 1% w/v active substance, 5% surfactant and 94% water. Higher concentrations of surfactant may be used to load more active substance.
[0049] The surfactants described above have been found to create a clear nanoemulsion when used according to the techniques described herein. Other surfactants may be used to create a nanoemulsion having a small droplet size, but at least some such surfactants may not yield a clear nanoemulsion.
[0050] For example, other forms of polysorbates and/or poloxomers may be used instead of or in addition to polysorbate 80 and poloxamer 407. For example, the surfactant preparation may contain any of polysorbates 20, 40, 60, 80, 85 and/or any of poloxamers 105, 188, 238, 331, 333, 334, 335, 338, 407 and/or any of and polyethylene glycols 200, 300, 400, 600.
[0051] The cannabis-based preparation may be or include tetrahydrocannabinol (THC) resin. Additionally or alternatively, the cannabis-based preparation may be or include hemp oil, cannabidiol (CBD) resin, cannabidiol (CBD) or THC distilled, THC or CBD crystalline, any kinds of rare cannabinoids such as but not limited to cannabinol (CBN), cannabigerol (CBG), tetrahydrocannabivarin (THCV), tetrahydrocannabinolic acid (THCA), tetrahydrocannabiphorol (THCP), Tetrahydrocannabinol (THCC), cannabidiolic acid (CBDA), cannabivarin (CBV), cannabichromene (CBC) and combinations thereof and/or terpenes.
[0052] The cannabis-based preparation may include an antioxidant. The antioxidant may be or include alpha tocopherol (which may also be referred to as Vitamin E). Other antioxidants may be used instead of or in addition to alpha tocopherol. For example, the cannabis-based preparation may include any one or a combination of: ascorbyl palmitate, butylated hydroxytoluene, or butylated hydroxyanisole.
[0053] In at least some embodiments, the cannabis preparation includes alpha tocopherol without any other oily carrier. Alpha tocopherol may be added to prevent oxidation. The amount of alpha tocopherol may, for example, be approximately 0.04% by volume of the amount of the cannabis-based preparation, but the concentration may be varied.
[0054] At step 104, an organic phase is prepared. More specifically, the mixture created at step 102 is combined with a solvent.
[0055] For example, the mixture may be dissolved in a water miscible solvent such as ethanol or acetone. Ethanol has been used for reasons of volatility and safety but other solvents may be used. In some embodiments, the mixture may be dissolved in ethanol which is, conveniently, safe to use and easy to evaporate.
[0056] At step 106, the mixture that includes the solvent is passed through a filter to remove insoluble material. The mixture may be passed through a 0.22 to 0.45 micrometer membrane filter. Any material separated out by the filter may be discarded.
[0057] At step 108, an aqueous phase is prepared. The aqueous phase is prepared by measuring an appropriate volume of water by calculating the volume of all ingredients based on the formulation and then calculating an amount of water required for the formulation. A chelating agent and a preservative may be included in the aqueous phase. For example, Ethylenediaminetetraacetic acid (EDTA) is a chelating agent that can chelate
a small amount of metal to prevent oxidation and increase the effects of the antioxidant. The preservative may, for example, be benzoic acid or sorbic acid. Other preservatives may be used. By way of example, the preservative may be any one or a combination of: 1) Sorbic acid and its salts like sodium sorbate, potassium sorbate; 2) Benzoic acid and Benzoic acid derivatives like sodium benzoate; 3) Parabens: Methyl paraben, Propyl paraben; 4) Benzalkonium chloride; and 5) Cetylpryidinium bromide [0058] EDTA may have a concentration of approximately 0.005% to 0.01% and the benzoic acid may have a concentration of approximately 0.02% to 0.5% and the sorbic acid may have a concentration of 0.1 -0.2%.
[0059] At step 110, the organic phase (i.e. the mixture that includes the solvent) is slowly added to the aqueous phase (e.g., in a dropwise manner). The organic phase is added to the aqueous phase dropwise, preferably at a rate of no faster than 1.4 milliliters per minute (organic phase) to make 100 milliliter batch of concentrated nanoemulsion. If the organic phase is added to the aqueous phase too rapidly, there may not be enough time for the solvent to diffuse into the water which may result in a final product having a larger droplet size and/or that may not be clear.
[0060] The organic phase may be added to the aqueous phase using a peristaltic pump, a syringe or mist. The organic phase may be added to the aqueous phase under stirring. The stirring may, for example, be performed with any kind of mechanical agitator. [0061] After the organic phase is completely added to the aqueous phase, stirring may continue to ensure diffusion of the organic phase is complete. For example, stirring may continue for thirty minutes or more.
[0062] At step 112, evaporation is performed on the mixture that includes the organic phase and the aqueous phase. For example, the water miscible solvent, such as ethanol or acetone, may be evaporated at 35 to 40 degrees Celsius by rotary evaporator. The
evaporation may continue for 30 minutes or more. The evaporation step may end when all of the solvent is evaporated. While the evaporation step could continue even after the solvent is completely removed, continuing the evaporation after the solvent is removed may have an adverse effect on stability of the nanoemulsion and/or may unnecessarily use energy or equipment.
[0063] At step 114, the volume of the mixture remaining after evaporation may be measured and water may be added to adjust the volume. For example, for a 100 mL batch of nanoemulsion, if 1 to 2 mL were lost on evaporation (at step 112), as may be determined using a graduated cylinder, the volume may be adjusted 1 to 2 mL with water to account for the loss of volume due to evaporation.
[0064] At step 116, the nanoemulsion may be added to and stored in one or more closed containers. The container may be configured to block external light and/or may prevent oxygen from entering the container. In some embodiments, the container may be an amber tinted or colored container. In at least some embodiments, the container may be nitrogen flushed or vacuum sealed to remove any gaseous oxygen from within the container.
[0065] Referring now to FIG. 2, a graph illustrating the size distribution of droplets for a TF1C nanoemulsion containing 7.5 mg of TF1C per milliliter is illustrated. It may be noted that the nanoemulsion could have other amounts of TF1C. For example, the nanoemulsion may preferably contain 5 mg to 7.5 mg of TF1C per m though other amounts of TF1C are also possible. For example, a stable nanoemulsion may be made up to at least 10 mg/mL if the starting material is pure isolate. The nanoemulsion has been prepared using the techniques described herein and it may be seen that the droplet size is relatively small (e.g., less than 100 nanometers).
[0066] Similar results to those illustrated in FIG. 2 for TF1C are also illustrated for hemp oil (FIG. 3) containing 1% weight by volume Flemp Oil, and for CBD crystallized nanoemulsion (FIG. 4) containing 7.5 mg of crystallized CBD per milliliter, and for CBD resin nanoemulsion (FIG. 5) containing 10 mg CBD resin per milliliter, and for CBD resin and CBD crystallized nanoemulsion (FIG. 6) containing 5 mg of CBD resin and CBD crystallized per milliliter and CBD crystallized nanoemulsion (FIG. 7) containing 7.5 mg of CBD resin and CBD crystallized per milliliter.
[0067] Reference will now be made to FIG. 8 which illustrates a further method 800 of preparing a cannabis-based nanoemulsion. The method 800 may, for example, be used to prepare a terpene-based nanoemulsion. Conveniently, the method 800 of FIG. 8 does not use a solvent and does not require an evaporation step. The method 800 of FIG. 8 may avoid evaporation of certain ingredients, such as terpenes.
[0068] The technique described above with reference to FIG. 8 could also be used for non-terpene based nanoemulsions. Flowever, this technique may produce larger droplets than the solvent-based method (i.e., the phase inversion method) described above with reference to FIG. 1. The solvent may help to diffuse oil allowing for smaller droplet sizes. [0069] At step 802, a surfactant preparation may be prepared by melting one or more surfactants. For example, one or more surfactants may be melted at approximately forty five (45) degrees Celsius. For example, the one or more surfactants may be melted at above forty three (43) degrees Celsius. By way of further example, the one or more surfactants may be melted at between 43 and 46 degrees Celsius. While greater temperatures may be used to melt the surfactant(s), lower temperatures may prevent instability of the preparation. Further, melting of surfactants may not be required for all implementations. For example, melting may not be required if the surfactants used are liquid at room temperature.
[0070] The surfactants used in the surfactant preparation may preferably include polysorbate 80 and poloxamer 407. The surfactant preparation preferentially contains polysorbate 80, and may also include (but not limited to) various forms of: polysorbates (20, 40, 60, 85), any kinds of poloxamers (105, 188, 238, 331, 333, 334, 335, 338, 407) and polyethylene glycols (200, 300, 400, 600). The surfactant preparation may include poloxamer 407. In at least some embodiments, the surfactant preparation includes polysorbate 80 and poloxamer 407 in a ratio of between three 3 parts polysorbate 80 to 0.75 part poloxamer 407 (3:0.75) to four (4) parts polysorbate 80 to one (1) part poloxamer 407 (4:1).
[0071] In at least some embodiments, the surfactant preparation includes a co surfactant. The co- surfactant may be a diethylene glycol derivative such as an ethylene- series of glycol ether. For example, it may be or include diethylene glycol monoethyl ether such as Transcutol FIP(TM) or Carbitol. Other co- surfactants may be used. The co surfactant may be combined in the surfactant preparation with the one or more surfactants in a ratio of between 4.5 parts surfactant to 0.5 parts co-surfactant and 5 parts surfactant to 1.6 parts co-surfactant.
[0072] After the surfactants are melted, the surfactants may be stirred (during step 802) until the mixture (which may also be referred to as the surfactant preparation) becomes clear. It has been found that clarity occurs after approximately five minutes of stirring in laboratory environments. Flowever, the length of time required may vary. Most typically, the length of time is less than 15 minutes at 45 degrees Celsius depending on the level of impurities in the cannabis extract, with resins containing waxes taking longer.
[0073] After the surfactant mixture becomes clear, the mixture may be cooled. For example, the mixture may be cooled to room temperature (about 20 to 25 degrees Celsius) during step 802. Cooling of the mixture may prevent loss of the terpenes.
[0074] The surfactant preparation that is prepared at step 802 may be combined with a cannabis-based preparation at step 804 to create a mixture, which may be referred to as the organic phase. In some embodiments, the cannabis-based preparation may be a terpene-based preparation such as a terpene concentrate. Terpenes are organic compounds that impart aroma and flavor to cannabis plants. The term terpene concentrate pertains to the concentrated terpenes rendered from different cannabis strains. The described method should be compatible with terpene concentrates from any cannabis strain, terpene isolates (single terpenes isolated from a concentrated mixture), and formulated terpene mixtures derived from the combination of a set of desired terpene isolates. The phase inversion method has been used to make different kinds of cannabinoid nanoemulsions including those containing terpenes. In some embodiments, nanoemulsions with 1-2% terpene concentrates are made with different types of terpenes using the method 800, and diluted into different water based mixtures such as beverages. This method may be particularly useful for preparation of terpene nanoemulsions because of the volatile nature of terpenes, which makes the use of evaporation and heat inappropriate.
[0075] At step 806, an aqueous phase is prepared. The aqueous phase is prepared by measuring an appropriate volume of water (e.g., by calculating the volume of all ingredients based on the formulation and then calculating how much water is needed for the formulation and adding EDTA and a preservative in at least some embodiments. The preservative may, for example, be benzoic acid, such as benzoic acid at a concentration of 0.05%. The preservative may, for example, aid in avoiding microbial growth and prevent oxidation. Other preservatives may be used. By way of example, the preservative may be any one or a combination of: 1) Sorbic acid and its salts like sodium sorbate, potassium sorbate; 2) Benzoic acid and Benzoic acid derivatives like sodium benzoate; 3) Parabens:
Methyl paraben, Propyl paraben; 4) Benzalkonium chloride (for non-oral applications); and 5) Cetylpryidinium bromide
[0076] At step 808, the aqueous phase is slowly added to the organic phase (i.e., the mixture that includes the surfactant preparation and the cannabis-based preparation). For example, the aqueous phase may be added in a dropwise manner. For example, the aqueous phase may preferably be added no faster than 1.4 mL per minute to make 100 mL batch of concentrated nanoemulsion. If the aqueous phase is added to the organic phase too rapidly, there may not be enough time for the organic phase to diffuse in the water which may result in a final product having a large droplet size and/or that may not be clear. [0077] The aqueous phase may be added to the organic phase using a peristaltic pump or with a syringe.
[0078] After the aqueous phase is completely added to the organic phase, stirring may occur to ensure that diffusion of the organic phase is complete. For example, stirring may continue for thirty minutes or more.
[0079] At step 810, the nanoemulsion may be added to and stored in one or more closed containers. The container may be configured to block external light and/or may prevent oxygen from entering the container. In some embodiments, the container may be an amber tinted or coloured container. In at least some embodiments, the container may be nitrogen flushed or vacuum sealed to remove any gaseous oxygen from within the container.
[0080] Conveniently, the nanoemulsions prepared according to the methods 100, 800 described herein may be prepared without the use of a homogenizer or other sophisticated equipment (e.g., without the use of a homogenizer, sonicator or microfluidizer). Conveniently, in at least some embodiments, the nanoemulsions may be clear and/or may have a small droplet size. A small droplet size may allow for a faster onset for active
ingredients in the nanoemulsions. That is, the effects of the CBD, THC and/or terpenes may occur more rapidly where the droplet size is relatively small.
[0081] The nanoemulsions prepared using the techniques described herein may be in liquid form. However, such nanoemulsions may be processed into another form, such as a solid form. For example, the liquids may be processed to create a sublingual film or spray, lotions, ointments and cosmetics, or a foam.
[0082] Conveniently, the nanoemulsions prepared according to the methods described herein may be stable in water or soda. This may, for example, allow the nanoemulsion to be added to water or a soda before being ingested or otherwise consumed.
[0083] Conveniently, the nanoemulsions prepared according to the methods described herein may be sterilized using filtration (i.e., by passing the nanoemulsions through a filter such as a 0.45 micrometer filter). Filtration is possible due to the small droplet size associated with nanoemulsions. Sterilization by filtration may be used instead of, for example, thermal sterilization techniques. In at least some embodiments, methods described herein may include sterilizing a nanoemulsion prepared according to the techniques described herein using filtration.
[0084] The cannabis-based concentrated stock nanoemulsions described herein can be diluted in a matrix of choice like beverages, sublingual strips, nasal sprays, cosmetic or topical products. For example, 1 ml of 1% stock solution could be diluted with 354 ml beverage for a 355 ml can with 10 mg cannabinoid.
[0085] The nanoemulsions described herein may be used by a human or animal. For example, the nanoemulsions may be used as oral, buccal, topical, rectal, nasal solution and/or spray, eyedrops, etc. The nanoemulsion may be administered, for example, for medicinal benefits. The nanoemulsions may, for example, be added to a food product such as a baked good or a beverage, such as water, soda, non-alcoholic beer, breezers, or
coolers. Accordingly, methods of creating products, such as beverages, edibles, cosmetics, topicals, sublingual sprays, nasal sprays, eye drops, etc. using concentrated nanoemulsions prepared using techniques described herein are contemplated. In some implementations, preparing such products may include diluting the concentrated nanoemulsions.
[0086] The nanoemulsions described herein may be used, for example, to treat a variety of medical conditions. For example, the nanoemulsions may be used to treat one or more of: multiple sclerosis (MS), nausea, vomiting, loss of appetite for F1IV patients and/or seizures. The nanoemulsions may be used to treat other conditions apart from those specifically recited herein.
[0087] The nanoemulsions described herein may be used by a human or animal. For example, the nanoemulsions may be ingested (i.e., used orally). The nanoemulsions may be administered, for example, for medicinal benefits.
[0088] The nanoemulsions described herein may be used, for example, to treat a variety of medical conditions. For example, the nanoemulsions described herein may be used for the treatment or amelioration of symptoms of medical conditions. Such symptoms may include any one or a combination of inflammation, lack of appetite, nausea, vomiting, pain including chronic pain, or muscle spasms. For example, the cannabis based products described herein may be used as part of a treatment plan (including to manage symptoms) for conditions such as multiple sclerosis, glaucoma, acquired immunodeficiency syndrome (AIDS), neuropathic conditions, cancer, acne, diseases of malnutrition, arthritis, or spinal cord injury. It can be appreciated that cannabis based products can be used for treatment of other symptoms or other conditions. Accordingly, the nanoemulsions described herein may be used for the treatment of any one or more medical conditions or systems, such as those listed above. For example, the nanoemulsions may be ingested by a patient suffering from such a symptom or condition.
[0089] The various embodiments presented above are merely examples. Variations of the innovations described herein will be apparent to persons of ordinary skill in the art, such variations being within the intended scope of the present application. In particular, features from one or more of the above-described example embodiments may be selected to create alternative example embodiments including a sub-combination of features which may not be explicitly described above. In addition, features from one or more of the above- described example embodiments may be selected and combined to create alternative example embodiments including a combination of features which may not be explicitly described above. Features suitable for such combinations and sub-combinations would be readily apparent to persons skilled in the art upon review of the present application as a whole. The subject matter described herein and in the recited claims intends to cover and embrace all suitable changes in technology.
Claims
1. A method of preparing a cannabis-based nanoemulsion, the method comprising: combining a surfactant preparation with a cannabis-based preparation to create a mixture; combining the mixture with a solvent to make an organic phase; adding the organic phase to an aqueous phase; and evaporating the solvent.
2. The method of claim 1 , wherein the surfactant preparation includes polysorbate 80.
3. The method of claim 1 , wherein the surfactant preparation includes poloxamer 407.
4. The method of claim 1, wherein the surfactant preparation includes polysorbate 80 and poloxamer 407 in a ratio of between 3 parts polysorbate 80 to 0.75 parts poloxamer 407 (3:0.75) to 4 parts polysorbate 80 to 1 part poloxamer 407 (4:1).
5. The method of claim 1 , wherein the surfactant preparation includes a co- surfactant.
6. The method of claim 5, wherein the co-surfactant is diethylene glycol monoethyl ether.
7. The method of claim 5, wherein the co-surfactant is combined in the surfactant preparation with one or more surfactants in a ratio of between 4.5 parts surfactant to 0.75 parts co-surfactant and 5 parts surfactant to 1.6 parts co-surfactant.
8. The method of claim 1, wherein the cannabis-based preparation includes one or more of: tetrahydrocannabinol (THC) distilled resin; hemp oil; cannabidiol (CBD) distilled resin; cannabidiol (CBD) distilled crystalline; or
terpenes.
9. The method of claim 1, wherein the cannabis-based preparation includes an antioxidant.
10. The method of claim 9, wherein the antioxidant is alpha tocopherol.
11. The method of claim 1, wherein the cannabis-based preparation includes alpha tocopherol without any other oily carrier.
12. The method of claim 1, wherein the solvent is water- miscible.
13. The method of claim 1, wherein the solvent is ethanol.
14. The method of claim 1, wherein the solvent is acetone.
15. The method of claim 1, further comprising, prior to adding the organic phase to the aqueous phase, filtering the mixture.
16. The method of claim 15, wherein the filtering is performed using a 0.22 to 0.45 micrometer membrane filter.
17. The method of claim 1, further comprising, prior to adding the organic phase to the aqueous phase, preparing the aqueous phase by combining a preservative with water.
18. The method of claim 17, wherein the preservative is benzoic acid, a benzoic acid derivate, or sorbic acid.
19. The method of claim 1, wherein the organic phase is added to the aqueous phase in a dropwise manner.
20. The method of claim 19, wherein the organic phase is added to the aqueous phase at a rate of not faster than 1.4 mL per minute to make 100 mL batch of concentrated nanoemulsion.
21. The method of claim 1, wherein the organic phase is added to the aqueous phase using a peristaltic pump.
22. The method of claim 1, wherein the cannabis-based nanoemulsion is prepared without the use of any of a homogenizer, sonicator and microfluidizer.
23. A cannabis-based nanoemulsion produced according to the method of any one of claims 1 to 22.
24. A method of preparing a cannabis-based nanoemulsion, the method comprising: preparing a surfactant preparation by melting one or more surfactants; combining the surfactant preparation with a cannabis-based preparation to create an organic phase; and adding an aqueous phase to the organic phase.
25. The method of claim 24, wherein preparing the surfactant preparation includes: after melting, stirring the melted surfactants until the surfactant preparation becomes clear.
26. The method of claim 25, wherein preparing the surfactant preparation includes: after the surfactant becomes clear, cooling the surfactant to room temperature prior to adding the aqueous phase to the organic phase.
27. The method of claim 24, wherein the one or more surfactants include polysorbate 80.
28. The method of claim 24, wherein the one or more surfactants includes poloxamer 407.
29. The method of claim 24, wherein the one or more surfactants includes polysorbate 80 and poloxamer 407 in a ratio of between 3 parts polysorbate 80 to one part poloxamer 407 (3:0.75) and four parts polysorbate 80 to one part poloxamer 407 (4:1).
30. The method of claim 24, wherein the cannabis-based preparation is a terpene-based preparation.
31. The method of claim 24, further comprising, prior to adding the aqueous phase to the organic phase, preparing the aqueous phase by combining a preservative with water.
32. The method of claim 31, wherein the preservative is benzoic acid, a benzoic acid derivative or sorbic acid.
33. The method of claim 24, wherein the aqueous phase is added to the organic phase in a dropwise manner.
34. The method of claim 33, wherein the aqueous phase is added to the organic phase at a rate of not faster than 1.4 mL per minute to make 100 mL batch of concentrated nanoemulsion.
35. The method of claim 24, wherein the aqueous phase is added to the organic phase using a peristaltic pump.
36. The method of claim 24, wherein the cannabis-based nanoemulsion is prepared without the use of any of a homogenizer, sonicator and microfluidizer.
37. A cannabis-based nanoemulsion produced according to the method of any one of claims 1 to 36.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CA2021/050182 WO2022174323A1 (en) | 2021-02-19 | 2021-02-19 | Clear cannabis-based nanoemulsion |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CA2021/050182 WO2022174323A1 (en) | 2021-02-19 | 2021-02-19 | Clear cannabis-based nanoemulsion |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022174323A1 true WO2022174323A1 (en) | 2022-08-25 |
Family
ID=82932155
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2021/050182 WO2022174323A1 (en) | 2021-02-19 | 2021-02-19 | Clear cannabis-based nanoemulsion |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022174323A1 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104208087B (en) * | 2014-09-17 | 2017-05-31 | 句容亿格纳米材料厂 | A kind of taxol composite nano-emulsion and preparation method thereof |
CN110269840A (en) * | 2019-06-15 | 2019-09-24 | 云南飞久逍科技有限公司 | A kind of cannabidiol CBD nano-emulsion and preparation method thereof |
CN110559229A (en) * | 2019-09-21 | 2019-12-13 | 云南辰锦威生物科技有限公司 | Night cream containing cannabidiol CBD nano-emulsion and preparation method thereof |
WO2020037408A1 (en) * | 2018-08-20 | 2020-02-27 | Hexo Operations Inc. | Cannabis-infused product with controlled cannabinoid profile user experience |
WO2020081550A1 (en) * | 2018-10-15 | 2020-04-23 | New Frontier Brewing Company, Llc | Nanoemulsion cannabis formulations and methods of making same |
US10738268B2 (en) * | 2016-08-21 | 2020-08-11 | Insectergy, Llc | Cannabis nanoemulsion methods |
-
2021
- 2021-02-19 WO PCT/CA2021/050182 patent/WO2022174323A1/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104208087B (en) * | 2014-09-17 | 2017-05-31 | 句容亿格纳米材料厂 | A kind of taxol composite nano-emulsion and preparation method thereof |
US10738268B2 (en) * | 2016-08-21 | 2020-08-11 | Insectergy, Llc | Cannabis nanoemulsion methods |
WO2020037408A1 (en) * | 2018-08-20 | 2020-02-27 | Hexo Operations Inc. | Cannabis-infused product with controlled cannabinoid profile user experience |
WO2020081550A1 (en) * | 2018-10-15 | 2020-04-23 | New Frontier Brewing Company, Llc | Nanoemulsion cannabis formulations and methods of making same |
CN110269840A (en) * | 2019-06-15 | 2019-09-24 | 云南飞久逍科技有限公司 | A kind of cannabidiol CBD nano-emulsion and preparation method thereof |
CN110559229A (en) * | 2019-09-21 | 2019-12-13 | 云南辰锦威生物科技有限公司 | Night cream containing cannabidiol CBD nano-emulsion and preparation method thereof |
Non-Patent Citations (1)
Title |
---|
MCCLEMENTS DAVID JULIAN: "Enhancing Efficacy, Performance, and Reliability of Cannabis Edibles: Insights from Lipid Bioavailability Studies", ANNUAL REVIEW OF FOOD SCIENCE AND TECHNOLOGY, vol. 11, 28 February 2020 (2020-02-28), pages 45 - 70, XP055966749, DOI: 10.1146/annurev-food-032519- * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3582750B1 (en) | Oral cannabinoid formulations | |
US11819491B2 (en) | Dilutable formulations of cannabinoids and processes for their preparation | |
JP7265264B2 (en) | Method for selective extraction of cannabinoids from plant sources | |
US11013715B2 (en) | Nanoemulsion hydrophobic substances | |
EP3424494A1 (en) | Stable cannabinoid compositions | |
CA3117809A1 (en) | Polymer-based oral cannabinoid and/or terpene formulations | |
JP7487292B2 (en) | Stable medicinal cannabidiol compositions | |
US11458092B2 (en) | Composition with enhanced passenger molecule loading | |
EP3782607A1 (en) | Composition with enhanced passenger molecule loading | |
WO2022174323A1 (en) | Clear cannabis-based nanoemulsion | |
US20210093559A1 (en) | Self-emulsifying anhydrous intradermal depot gel | |
US20220142969A1 (en) | Water-soluble cannabinoid formulations and methods of their making | |
CN112870161B (en) | Cedarol nanoemulsion and optimized preparation method thereof | |
US20120264776A1 (en) | Menthol liquids composition | |
US20210059935A1 (en) | Self-emulsifying nano-emulsions | |
US20210046438A1 (en) | Surfactant Compositions and Methods for Emulsifying Cannabinoid Extracts as a Nano-Emulsion Material | |
US20210346446A1 (en) | Water soluble cannabinoid beverage composition | |
AU2018296678B2 (en) | Stable cannabinoid compositions | |
US20220183972A1 (en) | Nanoemulsion hydrophobic substances | |
CA3065074A1 (en) | Producing water soluble nano-emulsion particles containing cannabis/ cannabinoid oil or cannabis concentrate using ultrasonic processing technology and its use thereof in the beverage, edible powder and multipurpose cream | |
US20230355523A1 (en) | Self-emulsifying nano-emulsions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21926079 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21926079 Country of ref document: EP Kind code of ref document: A1 |